Physician profile
David Beckert
NPI 1154403475
$6,934.19
in general payments reported to CMS, 2019-2025
13 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $130 · 2021: $218 · 2022: $1,229 · 2023: $1,573 · 2024: $925 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,359.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,753.01 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,182.43 | 2022-2025 | Uzedy, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $697.99 | 2020-2025 | Ingrezza |
| Alkermes, INC. | $674.72 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $438.68 | 2022-2025 | Rexulti |
| Abbvie INC. | $353.46 | 2022-2024 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $346.97 | 2024-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $337.49 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $326.53 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $276.39 | 2019-2022 | |
| Axsome Therapeutics, INC. | $235.09 | 2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $183.81 | 2023 | Quviviq |
| Janssen Scientific Affairs, LLC | $127.62 | 2025 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Beckert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.